Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of XueBiJing injection in sepsis
ChiCTR1800015376Phase 4Not yet recruiting
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Jan 2018
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of xuebijing in sepsis, sponsored by Shanghai Institute of Materia Medica. Primary endpoint: Plasma concentration. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
xuebijing
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR1800015376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015376.